The market demand for the proposed vaccine candidate comes from three target groups.
- Travellers from industrialized countries to developing countries
- Military personnel (US & NATO, etc.) stationed in developing countries
- NGOs and governments of the developing countries where Shigella and ETEC infections are endemic
A large demand for vaccines
According to the “The Case for Investment in Enterotoxigenic Escherichia coli Vaccines” (PATH Study, 2004, funded by the Bill & Melinda Gates Foundation) if a successful ETEC vaccine will be launched to the market, global demand is estimated to reach approximately 118 million doses per year, with revenues peaking around $600 million in 12 years after launch.
The number of international travelers is increasing again. International tourist arrivals worldwide reached 940 million in 2010 and the UNWTO Tourism 2020 Vision forecasts that these numbers are expected to reach 1.6 billion by the year 2020. An estimated 80 million people travelled from industrialized countries to developing countries in 2010. This number may reach 190 million by 2020.
Among travel-related diseases, Traveller's Diarrhea (TD) is the most frequent illness for travelers. Approximately 24 to 40 million people worldwide are affected by TD, including 7.5 to 12.5 million from Europe and 9.5 to 15.9 million from the United States (source: Economic Aspects of Travelers’ Diarrhea, Journal of Travel Medicine, Volume 15, Issue 2, 2008, 110-118). TD can cause considerable damage by undermining travel itineraries, destroying business opportunities, and reducing tourist industry revenues.
Innovative aspect of Shigetec™
The major innovative aspect of the vaccine is the unique genetic mutations introduced to the Shigella vaccine strain that together render the bacterium non-pathogenic, non-invasive, at the same time more immunogenic than the natural form of Shigella. The genetic mutations independently cause full attenuation ensuring safety and stability for our vaccine candidate. The combination with ETEC antigens provides prevention of both ETEC and Shigella infections. The cumulative result is expected to be a very safe, highly immunogenic and broad spectrum oral vaccine that can be administered in a convenient way with no need of medical personnel.
Aws pre-seed funding
EveliQure received a Pre-seed grant from aws (Austria Wirtschaftsservice GmbH) for delivering a Proof-of-Concept (PoC) for their business idea.
EveliQure among the winning teams of “Best of Biotech 2012”
Vienna, 18th October 2012
EveliQure received positive feedback on its business idea and won the 3rd place in “Best of Biotech” - an international business plan competition with focus on Life Sciences, run by the Austria Wirtschaftsservice (aws) on behalf of the Austrian Federal Ministry of Economics, Family and Youth (BMWFJ).
Would you like to know more?
We are happy to discuss further with you.Contact us